MARKET

AVIR

AVIR

Atea Pharmaceuticals, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

79.35
-1.94
-2.39%
Opening 11:42 02/26 EST
OPEN
79.48
PREV CLOSE
81.29
HIGH
83.29
LOW
77.96
VOLUME
184.31K
TURNOVER
--
52 WEEK HIGH
94.17
52 WEEK LOW
24.15
MARKET CAP
6.29B
P/E (TTM)
-287.7067
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Allogene (ALLO) Q4 Earnings Top Estimates, Pipeline Advances
Zacks.com · 2h ago
Bayer's (BAYRY) Q4 Earnings Match Estimates, Sales Miss
Zacks.com · 1d ago
Horizon's (HZNP) Shares Rise on Q4 Earnings & Sales Beat
Zacks.com · 1d ago
bluebird (BLUE) Q4 Loss Narrower than Expected, Sales Miss
Zacks.com · 1d ago
Epizyme's (EPZM) Q4 Loss Wider than Expected, Sales Beat
Zacks.com · 1d ago
Cassava Sciences (SAVA) to Post Q4 Earnings: What's in Store?
Zacks.com · 3d ago
Bionano (BNGO) to Report Q4 Earnings: What's in the Offing?
Zacks.com · 4d ago
Bionano (BNGO) to Report Q4 Earnings: What's in the Offing?
Zacks.com · 4d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AVIR. Analyze the recent business situations of Atea Pharmaceuticals, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AVIR stock price target is 49.00 with a high estimate of 49.00 and a low estimate of 49.00.
EPS
Institutional Holdings
Institutions: 66
Institutional Holdings: 47.83M
% Owned: 60.36%
Shares Outstanding: 79.24M
TypeInstitutionsShares
Increased
0
0
New
66
47.83M
Decreased
0
0
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.24%
Pharmaceuticals & Medical Research
-0.76%
Key Executives
Chairman/Chief Executive Officer/Founder/Director
Jean-Pierre Sommadossi
Chief Financial Officer/Executive Vice President/Primary Contact
Andrea Corcoran
Executive Vice President
Steven Good
Senior Vice President
Jonae Barnes
Senior Vice President
Wayne Foster
Other
Janet Hammond
Other
Arantxa Horga
Other
John Vavricka
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
About AVIR
Atea Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing antiviral therapeutics to improve the lives of patients suffering from life-threatening viral infections. It is focused on development of orally available selective nucleotide prodrugs for difficult-to-treat, life-threatening viral infections, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Its lead product candidate, AT-527, is an orally administered, antiviral agent for the treatment of patients infected with SARS-CoV-2. It provides AT-787 for the treatment of hepatitis C. It offers AT-752 for the treatment of dengue, which is an oral, purine nucleotide prodrug for the treatment of dengue virus, a mosquito-borne viral infection. The Company is evaluating two lead compounds, AT-889 and AT-934, nucleoside pyrimidine prodrugs and other compounds for the treatment of respiratory syncytial virus (RSV).

Webull offers kinds of Atea Pharmaceuticals Inc stock information, including NASDAQ:AVIR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AVIR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AVIR stock methods without spending real money on the virtual paper trading platform.